The role of joint nerves and mast cells in the alteration of vasoactive intestinal peptide (VIP) sensitivity during inflammation progression in rats.
The present study examined the peripheral effects of vasoactive intestinal peptide (VIP) on rat knee joint blood flow during acute and chronic inflammation. The involvement of joint nerves and synovial mast cells on these effects was also investigated. Prior to blood flow assessment, animals were deeply anaesthetised with ethyl carbamate (urethane; 2 mg kg(-1) i.p.). Local application of VIP (10(-13)-10(-9) mol) onto the capsular surface of normal rat knee joints caused a dose-dependent increase in synovial perfusion with an ED50 of 1.2 x 10(-11) mol. The dilator effect of the peptide was transient with the maximal response occurring approximately 1 min after drug administration. VIP-induced vasodilatation was blocked by co-administration of the VIP receptor antagonist VIP(6-28) (10(-9) mol). The inhibitory effect of the antagonist was consistent across the entire VIP dose range (P=0.01). The vasoresponsiveness to VIP was significantly attenuated in acutely inflamed joints; however, surgical denervation of acutely inflamed knees re-established the vasodilator effect of the neuropeptide. Topical application of VIP to 1- and 3-week adjuvant monoarthritic knees produced a hyperaemic response, which was not significantly different from normal (P=0.06 and 0.73 for 1- and 3-week adjuvant treated joints, respectively). Stabilisation of synovial mast cells by disodium cromoglycate (cromolyn) pretreatment did not alter the vasoresponsiveness to VIP in acute or chronically inflamed joints. The vasodilatatory effect of VIP is lost during acute knee joint inflammation and this abrogated effect is neurally dependent. In the chronic phase of knee joint inflammation, VIP-mediated hyperaemia recovers to normal levels. Synovial mast cells do not influence the vasomotor effects of exogenously applied VIP in inflamed knee joints.
McDougall
Jason J
JJ
Department of Physiology and Biophysics, University of Calgary, 3330, Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1. mcdougaj@ucalgary.ca
Barin
Ali Kursat
AK
D000818:Animals; D001168:Arthritis / Q000503:physiopathology*; D006614:Hindlimb; D007596:Joints / Q000098:blood supply / Q000294:innervation*; D008297:Male; D008407:Mast Cells / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology
D014665:Vasodilator Agents; D014660:Vasoactive Intestinal Peptide
Int J Dermatol. 1994 May;33(5):361-6
8039976
J Rheumatol. 1985 Jun;12(3):406-11
2413204
Arthritis Rheum. 1995 May;38(5):699-709
7538298
Exp Physiol. 1995 May;80(3):341-8
7543760
Exp Physiol. 1995 May;80(3):349-57
7543761
J Physiol. 1995 Jul 15;486 ( Pt 2):473-82
7473211
Br J Pharmacol. 1995 Jul;115(6):945-52
7582525
Arthritis Rheum. 1996 Jul;39(7):1222-33
8670335
J Biol Chem. 1997 Feb 14;272(7):4043-9
9020112
Br J Pharmacol. 1997 May;121(1):29-34
9146883
Br J Pharmacol. 1997 Jul;121(6):1075-80
9249241
Anat Embryol (Berl). 1997 Oct;196(4):269-77
9363849
Am J Pathol. 1998 Feb;152(2):555-63
9466582
Pharmacol Rev. 1998 Jun;50(2):265-70
9647867
J Auton Nerv Syst. 1998 Aug 6;72(1):55-60
9760080
Am J Physiol. 1999 Mar;276(3 Pt 2):R745-52
10070135
J Anat. 1999 Feb;194 ( Pt 2):233-9
10337955
Peptides. 2004 Dec;25(12):2079-86
15572195
Arthritis Rheum. 1999 Nov;42(11):2418-29
10555038
Anat Rec. 2000 Sep 1;260(1):51-61
10967536
Regul Pept. 2001 May 5;99(1):9-15
11257309
Nat Med. 2001 May;7(5):537-8
11329051
Nat Med. 2001 May;7(5):563-8
11329057
J Orthop Res. 2001 May;19(3):372-8
11398848
J Clin Invest. 2003 Jan;111(1):35-41
12511586
Am J Physiol Regul Integr Comp Physiol. 2003 Jun;284(6):R1477-85
12573980
J Allergy Clin Immunol. 2003 May;111(5):1099-105
12743576
Neurosci Lett. 2003 Jun 19;344(1):21-4
12781912
Arthritis Res Ther. 2003;5(6):R317-28
14680506
Am J Physiol Regul Integr Comp Physiol. 2004 Apr;286(4):R634-41
14670807
Naunyn Schmiedebergs Arch Pharmacol. 1985 Dec;331(4):364-8
2419771
Ann Rheum Dis. 1986 Aug;45(8):637-40
2874778
J Neurosci. 1986 Dec;6(12):3423-9
3794780
J Pharmacol Exp Ther. 1988 Jan;244(1):133-7
2447273
Peptides. 1989 Mar-Apr;10(2):441-6
2474155
Ann Rheum Dis. 1989 Nov;48(11):928-32
2480755
J Neurosci Res. 1990 Jul;26(3):301-7
2398510
Scand J Rheumatol. 1991;20(5):326-35
1947895
Histol Histopathol. 1991 Oct;6(4):469-76
1725138
Br J Pharmacol. 1992 Jul;106(3):746-50
1380389
Brain Res Mol Brain Res. 1992 Nov;16(1-2):143-9
1281253
Neuroscience. 1993 Jan;52(2):443-9
7680789
Peptides. 1993 Jul-Aug;14(4):755-62
8234021
J Neurosci Methods. 1993 Aug;49(1-2):5-10
8271831
Science. 1970 Sep 18;169(3951):1217-8
5450698
Proc Natl Acad Sci U S A. 1976 Sep;73(9):3197-200
787988
Am J Physiol. 1980 Jul;239(1):H73-80
7396021
Am J Obstet Gynecol. 1981 Jan 15;139(2):182-8
6161538
Acta Physiol Scand. 1981 May;112(1):65-70
7282406
Br J Pharmacol. 1982 Nov;77(3):505-9
6958342
Naunyn Schmiedebergs Arch Pharmacol. 1983 Mar;322(2):153-7
6191225
Science. 1984 Nov 2;226(4674):547-9
6208609
J Immunol. 1985 Aug;135(2 Suppl):843s-847s
2409171
Regul Pept. 1995 Jan 5;55(1):85-102
7536950